Companies: 10,795·Total market cap: $144.5T
Sanofi

Sanofi

SNYNASDAQHealthcare● Active
$45.02
+$0.64(+1.44%)
Market Cap$108.4B
P/E Ratio—
52W High$52.68
52W Low$42.28
Cash on HandFinancialsRevenue

Sanofi (SNY) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

SNY · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$7.66B▼ -3.4% vs prior year
FY · as of Dec 31, 2025 · Reported in EUR
Cash & Cash Equiv. (CCE)
$7.66B
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
-3.4%
vs prior fiscal year
Latest Quarter
$5.54B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in EUR

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$7.66BCash on Hand
Total Debt$21.79BTotal Debt
Net Cash / Net Debt−$14.13BNet Debt Position
Cash vs Debt Ratio
Cash 26%Debt 74%

Sanofi carries a net debt position of $14.13B. Total debt ($21.79B) exceeds cash on hand ($7.66B). Sanofi cash vs debt ratio: 26% cash / 74% debt.

Net Cash = Cash & ST Investments − Total Debt$7.66B − $21.79B = −$14.13B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
SNY annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$7.66B-3.4%
Dec 31, 2024$7.93B-9.0%
Dec 31, 2023$8.71B-31.6%
Dec 31, 2022$12.74B+26.1%
Dec 31, 2021$10.10B-27.4%
SNY cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%
#3
Sanofi
SanofiYOU
SNY
$7.66B7.1%
#4
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Sanofi (SNY) cash on hand as of December 31, 2025 is $7.66B, comprising $7.66B in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Sanofi cash and short-term investments on the balance sheet (10-K filing). Also referred to as Sanofi cash reserves or cash position.

Sanofi annual cash on hand history shows decreased -3.4% in 2025: decreased -3.4% in 2025. Sanofi cash reserves in 2025 reflect the company's capital allocation strategy.

Sanofi carries total debt of $21.79B against cash of $7.66B, resulting in a net debt position of -$14.13B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

SNY cash on hand · 5 questions

As of December 31, 2025, Sanofi (SNY) has $7.66B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $7.66B in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $5.54B. Data sourced from the annual 10-K filing via FMP.

SNY cash on handSNY cash reservesSNY cash 2025how much cash does SNY have

▸ Source: FMP /balance-sheet-statement · US GAAP · Sanofi · Sanofi SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025